Call Toll Free: 1-800-838-0800
From anywhere in the US

Azacitidine Treatment “Significantly Extends Overall Survival” For Myelodysplastic Syndromes and Acute Myeloid Leukemia Patients

This article discusses recent studies on the success of azacitidine (Vidaza®) treatment in reducing transfusion dependency, and increasing overall survival in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients.

Data presented at the 14th Congress of the European Society of Hematology demonstrate that treatment with azacitidine (Vidaza®) significantly extends overall survival and helps patients with myelodysplastic syndromes (MDS) become or remain red blood cell transfusion independent. Patients who benefited included those with higher-risk MDS or acute myeloid leukaemia (AML) with 20-30% blasts, as defined by the World Health Organization (WHO).
“The presentations at EHA this year continue to support the clinical benefit associated with Vidaza in MDS, including significantly extended overall survival…

Read the full article at ecancermedicalscience.com.

 

 

Tags: , , ,

This entry was posted by David Austin on Sunday, June 21st, 2009 at 1:50 am and is filed under acute myeloid leukemia, AML, Myelodysplastic Syndromes, Treatment . You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply